|
|
101 College Road East
New Jersey, 08540 USA
phone:(609) 228-8220
fax:(609) 228-8221
|
|
| Symbol |
NCST |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.nucryst.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Nanocrystalline technology |
|
| Management |
| Thomas E. Gardner, Chairman, President and CEO; David Holtz, Vice President and Chief Financial Officer (CFO); Carol Amelio, Vice President, General Counsel and Corporate Secretary; David C. McDowell, Vice President, Manufacturing Operations |
| |
|
|
|
|
|
|
|
| Keywords |
| nanotechnology, dermatology |
|
|
|
| Description |
|
NUCRYST Pharmaceuticals Corp. ("Nucryst") (TSX:NCS / NASDAQ:NCST) 9. February 2010 announced the completion of the previously announced amalgamation (the "Amalgamation") of Nucryst with 1499642 Alberta Ltd. ("1499642"), a wholly-owned subsidiary of the Westaim Corporation ("Westaim"),
NUCRYST Pharmaceuticals develops pharmaceutical products based on noble metal nanocrystalline technology. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
